Arno Therapeutics, Inc. announced that Alexander Zukiwski, M.D., has been appointed as the interim Chief Executive Officer effective immediately. Dr. Zukiwski will continue in his role as Vice President and Chief Medical Officer of the company. Dr. Zukiwski has an extensive background in pharmaceuticals and biotechnology over a distinguished 19 year career, including serving as Executive Vice President, Clinical Research, and Chief Medical Officer at MedImmune, Inc., as well as positions of increasing responsibility at Johnson & Johnson Pharmaceutical Research & Development, LLC (JJPRD) and Ortho Biotech.

Dr. Zukiwski replaces Mr. Glenn Mattes, who is leaving to pursue other opportunities. In addition to the appointment of Dr. Zukiwski, Mr. Lawrence Kenyon, Arno's Chief Financial Officer, was named Chief Operating Officer, expanding his duties to include day-to-day responsibility of the company's business-related functions. Mr. Kenyon has an extensive financial and operations background in the pharmaceutical and biotech industries spanning 25 years.

Mr. Randy Thurman, Vice Chairman of Arno's Board of Directors, will also take on a more active role, first overseeing the transition and then working with the board and management to ensure that Company priorities are effectively executed. Mr. Thurman has over 20 years of CEO leadership experience in the pharmaceutical, biotechnology and life sciences industry.